Minimal and small size invasive breast cancer with no axillary lymph node involvement: The need for tailored adjuvant therapies

Annals of Oncology

Volumn 15, Issue 11, 2004, Pages 1633-1639

  Colleoni, Marco ^a   Rotmensz, N ^a   Peruzzotti, G ^a   Maisonneuve, P ^a   Viale, G ^b   Renne, G ^b   Casadio, C ^b   Veronesi, P ^a   Intra, M ^a   Torrisi, R ^a   Goldhirsch, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Adjuvant therapy; Breast cancer; Tumor size

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN DERIVATIVE; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DATA ANALYSIS; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; INTRADUCTAL CARCINOMA; LABELING INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; STATISTICAL ANALYSIS; SURVIVAL TIME; VASCULAR DISEASE;

EID: 9444239298     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh434     Document Type: Article

References (32)

1. Neville AM, Bettelheim R, Gelber RD et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. J Clin Oncol 1992; 10: 696-705.
2. Silvestrini R, Daidone MG, Luisi A et al. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 1995; 13: 697-704.
3. Early Breast Cancer Trialists' Collaborative Groups. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
4. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
5. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348: 1189-1196.
6. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-3365.
7. American Joint Committee on Cancer. Cancer Staging Manual, 5th edition. Philadelphia, PA: Lippincott-Raven Publishers 1997; 171-178.
8. Susan A, Silver MD, Fattaneh A, Tavassoli MD. Mammary ductal carcinoma in situ with microinvasion. Cancer 1998; 82: 2382-2390.
9. Werling RW, Hwang H, Yaziji H, Gown AM. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol 2003; 27: 82-90.
10. Rosen PP, Oberman H. Tumors of the Mammary Gland. Washington, DC: Armed Forces Institute of Pathology 1993.
11. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002; 41: 151.
12. Colleoni M, Orvieto E, Nolè F et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 1999; 35: 574-579.
13. Veronesi U, Paganelli G, Viale G. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-553.
14. Goldhirsch A, Wood WC, Senn HJ et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1995; 87: 1441-1445.
15. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998; 90: 1601-1608.
16. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-3827.
17. Mann GB, Port ER, Rizza C et al. Six-year follow-up of patients with microinvasive, T1a, and T1b breast carcinoma. Ann Surg Oncol 1999; 6: 591-598.
18. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S. Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol 1995; 13: 1144-1151.
19. Rosner D, Lane W. Predicting recurrence in axillary-node negative breast cancer patients. Breast Cancer Res Treat 1993; 25: 127-139.
20. Hery M, Delozier T, Ramaioli A et al. Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse? Breast 2002; 11: 442-448.
21. McGuire WL, Clark GM. Prognostic factors for recurrence and survival in axillary node-negative breast cancer. J Steroid Biochem 1989; 34: 145-148.
22. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
23. Lee AKC. Lymph node negative invasive breast carcinomal centimeter or less in size (T1a,bN0M0). Cancer 1997; 79: 761-771.
24. Rosner D, Lane WW, Penetrante R. Ductal carcinoma in situ with microinvasion: a curable entity using surgery alone without need for adjuvant therapy. Cancer 1991; 67: 1498-1503.
25. Bedwani R, Vana J, Rosner D et al. Management and survival of female patients with "minimal" breast cancer: as observed in the long-term and short-term surveys of the American College of Surgeons. Cancer 1981; 47: 2769-2778.
26. Jotti GS, Petit JY, Contesso G. Minimal breast cancer: a clinically meaningful term? Semin Oncol 1986; 13: 384-392.
27. Nevin JE, Pinzon G, Moran TJ, Baggerly JT. Minimal breast carcinoma. Am J Surg 1980; 139: 357-359.
28. Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 1990; 125: 1298-1302.
29. Solin LJ, Fowble BL, Yeh I-T et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 1992; 23: 961-968.
30. Boland GP, Chan KC, Knox WF et al. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg 2003; 90: 426-432.
31. Rodrigues N, Carter D, Dillon D et al. Correlation of clinical and pathologic features with outcome in patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2002; 54: 1331-1335.
32. Fisher B, Bryant J, Dignam JJ et al. National Surgical Adjuvant Breast and Bowel Project. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002; 20: 4141-4149.